Loading...
Explore Goldline Pharmaceutical SME IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Goldline Pharmaceuticals operates in the business of marketing pharmaceutical products under the "Goldline" brand. The company does not manufacture its products, but partners with third-party manufacturers who produce medicines based on Goldline's market research and specifications, ensuring quality and regulatory compliance.
Goldline's product range is diversified across five segments: Goldline Pharma (42 products for various specialties), Goldline Cardinal (54 products for specialties like Diabetology and Cardiology), Goldline Aayushman (18 products for pediatrics and general practice), Goldline InLife (22 products for critical care and super specialty surgery), and Goldline Wellness (10 products focused on supportive care in cancer therapy).
The company's industry focus is on marketing pharmaceutical products. Products are sold under the Goldline brand through a network of distributors, supplying to retailers and wholesalers, and also supporting hospitals and healthcare providers. Goldline currently works with 15 manufacturers and 7 distributors.
Key highlights of Goldline Pharmaceuticals include:
The company sells its products across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 12 May - 14 May 2026 |
| IPO Price Band | ₹41 - ₹43 per share |
| Fresh Issue | ₹11.02 crore |
| Offer For Sale | NIL |
| Total IPO Size | ₹11.61 crore |
| Face Value | ₹10 |
| Listing On | BSE SME |
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 12 May 2026 |
| IPO Closing Date | 14 May 2026 |
| Basis Of Allotment | 15 May 2026 |
| Refunds | 18 May 2026 |
| Demat Transfer | 18 May 2026 |
| IPO Listing Date | 19 May 2026 |
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 | 31 Dec 2025 |
|---|---|---|---|---|
| Assets | 19.39 | 22.93 | 26.28 | 27.40 |
| Total Income | 19.85 | 23.57 | 28.06 | 21.41 |
| Profit After Tax | 0.26 | 1.81 | 2.83 | 2.22 |
| EBITDA | 2.19 | 4.30 | 5.83 | 4.16 |
| NET Worth | 5.89 | 7.86 | 10.35 | 12.36 |
| Reserves and Surplus | 2.08 | 3.76 | 1.65 | 3.65 |
| Total Borrowing | 10.83 | 11.13 | 11.03 | 9.47 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|
| Goldline Pharmaceutical Ltd. | 10.46 | 4.11 | 27.38% | 12.39 |
| Chandra Bhagat Pharma Ltd. | 28.94 | 1.14 | 2.86% | 39.72 |
| Mono Pharmacare Ltd. | 7.57 | 1.75 | 9.9% | 17.66 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | 12,72,000 |
| Non-Institutional Investor (NII/HNI) | 3,90,000 |
| Retail Individual Investor (RII) | 9,00,000 |
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 1.31 |
| Non-Institutional Investor (NII/HNI) | 144.62 |
| Retail Individual Investor (RII) | 137.45 |
| Total | 98.8 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
Bigshare Services Private Limited
Phone: +91 22-62638200
Email: ipo@bigshareonline.com
Website: www.bigshareonline.com
Goldline Pharmaceutical Ltd.103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, – 440015https://www.goldlinepharma.in/+91 712 2786666info@goldlinepharma.in